Table 3.
Anticancer medications for breast cancer patients at Khartoum Oncology Hospital
| Medications | Frequency | Percent |
|---|---|---|
| Conventional therapy | ||
| (Cyclophosphamide/5-FU) + Doxorubicin or Doxorubicin + docetaxel | 30 | 15.0 |
| (Cyclophosphamide/5-FU) + Epirubicin + docetaxel | 35 | 17.5 |
| Docetaxel or paclitaxel | 21 | 10.5 |
| Paclitaxel/docetaxel + carboplatin | 8 | 4.0 |
| Gemcitabine + docetaxel or Gemcitabine carboplatin | 3 | 1.5 |
| Capecitabine | 6 | 3.0 |
| Vinorelbine | 2 | 1.0 |
| Hormonal therapy | ||
| Tamoxifen | 31 | 15.5 |
| Letrozole | 29 | 14.5 |
| Anastrozole | 18 | 9.0 |
| Tamoxifen or Letrozole + goserelin | 3 | 1.5 |
| HER2-targeted therapy | ||
| Trastuzumab | 9 | 4.5 |
| Trastuzumab + tamoxifen or letrozole | 5 | 2.5 |